What Is the First-Line Treatment for Chronic Myeloid Leukemia?
In newly diagnosed chronic-phase CML, the treatment decision centers on selecting a frontline regimen with defined molecular efficacy milestones. Current evidence supports multiple guideline-endorsed options, and the choice between them depends on individual patient considerations.
Treatment Approach
Frontline management is built around tyrosine kinase inhibitor (TKI) therapy. Current guidelines carry a category 1 recommendation for multiple TKI options as initial treatment of CML-CP. The specific agents, selection framework, and clinical considerations are detailed in the full protocol.
Molecular Response Targets
- Early molecular response: BCR::ABL1 transcripts (IS) <10% at 3 and 6 months
- Complete cytogenetic response (CCyR): BCR::ABL1 (IS) ≤1% at 12 months or later
- Major molecular response (MMR): BCR::ABL1 (IS) ≤0.1%
References
DOI: 10.1002/ajh.27443
- The four commercially available TKIs used as frontline treatment of CML include imatinib, dasatinib, bosutinib, and nilotinib.
- Current guidelines recommend any of the four TKIs, imatinib, dasatinib, bosutinib, or nilotinib, as good therapeutic options with a category 1 recommendation for the initial treatment of CML-CP.
- These include "early MR" milestones (BCR::ABL1 transcripts [IS] <10%) at 3 and 6 months and later molecular milestones (MR2 at 12+ months; MMR at 36–48 months).
- In several studies, the achievement of a CCyR (Ph-positive metaphases 0%; BCR::ABL1 transcripts [IS] ≤1%) at 12 months or later on TKI therapy was associated with a significant survival benefit compared with achievement of lesser degrees of response.
- Achievement of BCR::ABL1 transcripts [IS] ≤0.1% (MMR) is associated with modest improvements in event-free survival rates, possible longer durations of CCyR, but not with a survival benefit.
View source ↗